Recombinant AAV Vector Production Using Repeated Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing recombinant AAV vectors face challenges in achieving high titers suitable for practical application in gene therapy, requiring large numbers of producer cells and inefficient particle yields.
Innovation Solution
A method involving repeated transfections of cell cultures with optimized plasmid vectors, including heterologous nucleotide sequences and replication/packaging genes, combined with specific adenovirus helper functions, reduces reverse packaging and enhances vector yield.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If current technology is used for producing recombinant AAV vectors, then production can be performed with existing methods, but the particle yield per cell is low and large numbers of producer cells are required
Solution Approach 1:
The patent modifies key parameters of the production system by introducing optimized plasmid vectors with enhanced promoter sequences (CMV immediate early promoter, RSV promoter), modified ITR sequences, and optimized gene arrangements. These parameter changes in the genetic constructs lead to significantly improved particle yield per cell, addressing the contradiction between productivity and quantity of producer cells needed.
Solution Approach 2:
The patent performs preliminary optimization of the plasmid vectors before transfection, including designing plasmids with enhanced promoters, modified ITRs, and optimized gene arrangements. This preliminary action ensures that when the cells are transfected, they immediately have the capacity for high-level expression and efficient particle production, thereby increasing yield per cell without requiring more producer cells.
2Productivity
If repeated transfections are performed, then sustained gene expression and higher vector yields are achieved, but the production process becomes more complex
Solution Approach 1:
The patent implements periodic action by performing repeated transfections at scheduled intervals (e.g., every 2-3 days) to maintain sustained gene expression. This periodic reinforcement of transfection ensures continuous production of viral vectors while allowing the system to reset and maintain efficiency, achieving high vector yields through controlled repetition rather than continuous operation.
Solution Approach 2:
The patent maintains continuity of useful action by keeping the producer cells in culture and repeatedly transfecting them rather than using single transfection and discarding cells. This continuous utilization of the same cell population with repeated transfections sustains gene expression and vector production over an extended period, maximizing yield while managing process complexity through systematic repetition.
3Productivity
If standard plasmid vectors are used for transfection, then the process is simple, but reverse packaging of bacterial sequences occurs and particle yield is limited
Solution Approach 1:
The patent extracts and removes the problematic bacterial origin of replication sequences from the plasmid vectors, replacing them with eukaryotic replication origins. This extraction of harmful bacterial sequences prevents reverse packaging contamination while maintaining the essential plasmid functions needed for vector production, thereby increasing particle yield without contamination.
Solution Approach 2:
The patent changes the fundamental parameters of the plasmid vectors by replacing bacterial replication origins with eukaryotic ones (e.g., SV40 origin, EBV origin), and by modifying promoter sequences and ITR structures. These parameter changes fundamentally alter the plasmid behavior to prevent bacterial sequence packaging while enhancing eukaryotic expression, thus eliminating contamination and improving yield simultaneously.
Data Source
AI summary
The present invention relates to methods for the production of high titer recombinant viral vectors, more particularly recombinant AAV vectors, so that the methods can be effectively employed on a scale that is suitable for the practical application of gene therapy techniques.